May 4, 2020 / 10:24 PM / a month ago

BRIEF-Adverum Biotech Reports Positive Interim Data From Cohorts 1-3 Of Optic Phase 1 Trial Of Advm-022 Intravitreal Gene Therapy For Wet AMD

May 4 (Reuters) - Adverum Biotechnologies Inc:

* ADVERUM BIOTECHNOLOGIES REPORTS POSITIVE INTERIM DATA FROM COHORTS 1-3 OF OPTIC PHASE 1 TRIAL OF ADVM-022 INTRAVITREAL GENE THERAPY FOR WET AMD

* ADVERUM BIOTECHNOLOGIES INC - ROBUST EFFICACY AND EVIDENCE OF A DOSE RESPONSE FROM SINGLE INTRAVITREAL INJECTION (IVT) OF ADVM-022

* ADVERUM BIOTECHNOLOGIES INC - LONG-TERM DURABILITY BEYOND 1 YEAR FROM SINGLE IVT INJECTION OF ADVM-022 WITH ZERO RESCUE INJECTIONS IN COHORT 1

* ADVERUM BIOTECHNOLOGIES INC - ENCOURAGING EARLY DATA FROM COHORT 3

* ADVERUM BIOTECHNOLOGIES INC - PLANS TO INITIATE A PLANNED PHASE 1/2 CLINICAL TRIAL OF ADVM-022 FOR TREATMENT OF DIABETIC RETINOPATHY IN H2 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below